Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Robert K. who wrote (9693)	4/21/1999 4:58:00 PM
From: aknahow	Respond to of 17367

Annual report on XOMA web. Great job. In addition loads fast. IMO high human interest, clear explanations. Endotoxin paper available in PDF format.

To: Robert K. who wrote (9693)	4/21/1999 5:20:00 PM
From: aknahow	Respond to of 17367

While not new information I liked the emphasis. Based on encouraging preclinical results, we launched an aggressive effort to find development and marketing partners for our next two BPI products: I-PREX(tm) and Mycoprex(tm). LM&E Partners, an ophthalmic consulting firm, is assisting us with our licensing efforts for the I-PREX(tm) product. This is a topical ophthalmic formulation of rBPI21 for treating eye infections and preventing the growth of blood vessels into the cornea after corneal transplants or surgery. A focus group of ocular surgeons convened to discuss the product has expressed particular enthusiasm about its potential to enhance antibiotics and reverse antibiotic resistance. "Vector Securities International is assisting us in finding a partner for Mycoprex(tm). This BPI-derived broad-spectrum fungicidal compound has a unique mechanism of action that should reduce the likelihood of fungal resistance. In various animal models, it has shown potent and specific activity; it appears to be much safer than the only approved fungicidal product. Once we have secured partners, we hope to proceed into the clinic with both products."

To: Robert K. who wrote (9693)	4/21/1999 9:07:00 PM
From: aknahow	Read Replies (1) \| Respond to of 17367

Bob, ran into this on a site. "High temperature increases the permeability of cell membranes." Just one reason why a fever may be part of the defense mechanism. Natural BPI along with an already more permeability membrane, caused by a fever. Seems like another very good reason to vote against management! <g>

To: Robert K. who wrote (9693)	4/22/1999 12:59:00 PM
From: aknahow	Read Replies (1) \| Respond to of 17367

Gelonin, not necessarily Geniimune: UI - 98381927 AU - Pagliaro LC; Liu B; Munker R; Andreeff M; Freireich EJ; Scheinberg DA; Rosenblum MG TI - Humanized M195 monoclonal antibody conjugated to recombinant gelonin: an anti-CD33 immunotoxin with antileukemic activity. SO - Clin Cancer Res 1998;4(8):1971-6 AD - Division of Medicine, The University of Texas M.D. Anderson Cancer Center, Houston 77030, USA. AB - The recently characterized immunotoxin HuM195-gelonin consists of a humanized anti-CD33 monoclonal antibody conjugated to the single- chain plant toxin gelonin. Binding of the immunotoxin to hematopoiet- ic cells that express the CD33 differentiation antigen has been demonstrated and results in cytotoxicity due to ribosomal inactivati- on by gelonin. Blast cells from most patients with acute myelogenous leukemia express CD33, whereas normal stem cells necessary for maintenance of hematopoiesis do not. We asked whether an immunoconju- gate using recombinant gelonin rather than plant gelonin is toxic to acute myelogenous leukemia (AML) cell lines and primary AML blasts obtained from patients and exposed to the immunotoxin in vitro. The CD33pos cell lines HL60, OCI/AML2, and OCI/ AML5 showed decreased proliferation when exposed to immunotoxin for 24-72 h. The CD33neg cell line OCI/AML3 was relatively resistant to HuM195, and all cell lines were resistant to equimolar concentrations of unconjugated antibody and gelonin. Primary blast cultures from seven patients with AML had CD33 detectable on 75.7-99.8% of cells by flow cytometry, and all showed dose-dependent decreases in clonogenic cell survival during 24-h incubation with the immunotoxin. Cells selected for low CD33 expression by cell sorting or by prolonged incubation with immunotoxin could reexpress CD33 at baseline levels and remained sensitive to immunotoxin. We conclude that humanized M195 conjugated to recombinant gelonin has antileukemic activity and should be considered for clinical testing in Phase I trials. Same subject, same research, but with different URL: oncolink.com